EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeted therapy for lung cancer: Beyond EGFR and ALK

Mercedes Herrera-Juárez iD, Cristina Serrano-Gómez, Helena Bote-de-Cabo, Luis Paz-Ares

Cancer · 2023

DOI: 10.1002/cncr.34757 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2023. Verfasst von Mercedes Herrera-Juárez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 120 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precision oncology comprises the set of strategies that aim to design the best cancer treatment based on tumor biology. A recognized subset of patients with non‐small cell lung cancer (NSCLC) harbor actionable genomic aberrations that can benefit from targeted therapy. In lung cancer, epidermal growth factor receptor ( EGFR ) mutations and anaplastic lymphoma kinase ( ALK ) rearrangements are well characterized oncogenic drivers for which the therapeutic use of tyrosine kinase inhibitors has demonstrated improved outcomes compared with chemotherapy. Other druggable targets are also well characterized, and effective inhibitors have been developed and commercialized, leading to a paradigm shift in NSCLC treatment. Here, the authors provide a review of the oncogenic role of the most relevant molecular alterations in NSCLC and emerging treatments in this setting beyond EGFR‐driven and ALK‐driven diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansAnaplastic Lymphoma KinaseMutationPrecision MedicineErbB ReceptorsProtein Kinase InhibitorsMolecular Targeted Therapy

Stichwörter der Autor:innen

driver mutationsgenomic aberrationsnonsmall cell lung cancer (NSCLC)targeted therapytyrosine kinase inhibitors (TKI)

Substanzen

Anaplastic Lymphoma KinaseErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Department of Medicine, Complutense University, Madrid, Spain.

ORCID-Profile: Mercedes Herrera-Juárez

Zitieren

APA

Herrera-Juárez, M., Serrano-Gómez, C., Bote-de-Cabo, H., & Paz-Ares, L. (2023). Targeted therapy for lung cancer: Beyond EGFR and ALK. Cancer. https://doi.org/10.1002/cncr.34757

Vancouver

Herrera-Juárez M, Serrano-Gómez C, Bote-de-Cabo H, Paz-Ares L. Targeted therapy for lung cancer: Beyond EGFR and ALK. Cancer. 2023. doi:10.1002/cncr.34757

BibTeX
@article{HerreraJurez2023,
  author = {Herrera-Juárez, Mercedes and Serrano-Gómez, Cristina and Bote-de-Cabo, Helena and Paz-Ares, Luis},
  title = {Targeted therapy for lung cancer: Beyond EGFR and ALK},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34757}
}
Kostenlos starten →